Neovacs (ALNEV.PA) Stock Price

Neovacs Price

CLOSED
0.68EUR-0.04 (-5.71 %)
Market closed

Over the last 17 years Neovacs grew revenue by 4.9% annually, reaching 291,300.00 EUR. For Neovacs, the net margin of -11,299.1% is up versus -20,613.1% a few years ago. The stock trades about 172% above its 52-week low.

Neovacs stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Neovacs over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Neovacs stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Neovacs's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Neovacs Stock Price History
DateNeovacs Price
8/6/20260.68 EUR
8/5/20260.72 EUR
8/4/20260.76 EUR
7/31/20260.73 EUR
7/30/20260.74 EUR
7/29/20260.80 EUR
7/28/20260.78 EUR
7/27/20260.74 EUR
7/24/20260.74 EUR
7/23/20260.81 EUR
7/22/20260.70 EUR
7/21/20260.78 EUR
7/20/20260.81 EUR
7/17/20260.99 EUR
7/15/20261.00 EUR
7/14/20261.08 EUR
7/13/20261.13 EUR
7/10/20261.21 EUR
7/9/20261.34 EUR
7/8/20261.15 EUR
7/7/20261.25 EUR
7/6/20261.33 EUR
7/3/20261.30 EUR
7/2/20261.66 EUR
7/1/20261.31 EUR
6/30/20261.10 EUR
6/29/20261.46 EUR
6/26/20261.52 EUR
6/25/20261.89 EUR
6/24/20261.89 EUR
6/23/20261.89 EUR
6/22/20262.00 EUR
6/19/20262.00 EUR
6/18/20262.00 EUR
6/17/20262.00 EUR
6/16/20262.00 EUR
6/15/20262.00 EUR
6/12/20262.00 EUR
6/11/20262.00 EUR
6/10/20262.00 EUR
6/9/20262.00 EUR
6/8/20262.00 EUR
6/5/20262.00 EUR
6/4/20262.00 EUR
6/3/20262.00 EUR
6/2/20262.00 EUR
6/1/20262.00 EUR
5/29/20261.00 EUR
5/28/20261.00 EUR
5/27/20261.00 EUR
5/26/20261.00 EUR
5/25/20261.00 EUR
5/22/20261.00 EUR
5/21/20261.00 EUR
5/20/20260.50 EUR
5/19/20260.50 EUR
5/18/20260.50 EUR
5/15/20260.50 EUR
5/14/20260.50 EUR
5/13/20260.50 EUR
5/12/20260.50 EUR
5/11/20260.50 EUR
5/8/20260.50 EUR
5/7/20260.50 EUR
5/6/20260.50 EUR
5/5/20260.50 EUR
5/4/20260.50 EUR
4/30/20260.50 EUR
4/29/20260.50 EUR
4/28/20260.50 EUR
4/27/20260.50 EUR
4/24/20260.50 EUR
4/23/20260.50 EUR
4/22/20260.50 EUR
4/21/20260.50 EUR
4/20/20260.25 EUR
4/17/20260.50 EUR
4/16/20260.50 EUR
4/15/20260.50 EUR
4/14/20260.50 EUR
4/13/20260.50 EUR
4/10/20260.50 EUR
4/9/20260.50 EUR
4/8/20260.75 EUR
4/7/20260.75 EUR
4/2/20260.63 EUR
4/1/20260.75 EUR
3/31/20260.75 EUR
3/30/20260.63 EUR
3/27/20260.75 EUR
3/26/20260.75 EUR
3/25/20260.87 EUR
3/24/20260.87 EUR
3/23/20261.00 EUR
3/20/20261.12 EUR
3/19/20261.12 EUR
3/18/20261.12 EUR
3/17/20261.12 EUR
3/16/20261.25 EUR
3/13/20261.25 EUR
3/12/20261.37 EUR
3/11/20261.37 EUR
3/10/20261.50 EUR
3/9/20261.50 EUR
3/6/20261.37 EUR
3/5/20261.63 EUR
3/4/20261.88 EUR
3/3/20261.88 EUR
3/2/20261.88 EUR
2/27/20262.13 EUR
2/26/20262.25 EUR
2/25/20262.25 EUR
2/24/20262.25 EUR
2/23/20262.13 EUR
2/20/20262.00 EUR
2/19/20262.13 EUR
2/18/20262.00 EUR
2/17/20262.00 EUR
2/16/20262.00 EUR
2/13/20262.00 EUR
2/12/20262.25 EUR
2/11/20262.38 EUR
2/10/20262.75 EUR
2/9/20262.88 EUR
2/6/20263.12 EUR
2/5/20263.50 EUR
2/4/20264.00 EUR
2/3/20263.75 EUR
2/2/20263.62 EUR
1/30/20264.50 EUR
1/29/20264.87 EUR
1/28/20264.38 EUR
1/27/20264.25 EUR
1/26/20264.38 EUR
1/23/20264.63 EUR
1/22/20264.87 EUR
1/21/20265.13 EUR
1/20/20265.00 EUR
1/19/20265.62 EUR
1/16/20265.62 EUR
1/15/20267.00 EUR
1/14/20268.75 EUR
1/13/20267.75 EUR
1/12/20268.75 EUR
1/9/20269.00 EUR
1/8/20269.62 EUR
1/7/202610.00 EUR
1/6/202610.25 EUR
1/5/202610.63 EUR
1/2/202611.00 EUR
12/31/202510.88 EUR
12/30/202511.50 EUR
12/29/202512.00 EUR
12/24/202512.00 EUR
12/23/202512.25 EUR
12/22/202510.75 EUR
12/19/202511.25 EUR
12/18/202512.00 EUR
12/17/202511.75 EUR
12/16/202511.87 EUR
12/15/202513.38 EUR
12/12/202512.62 EUR
12/11/202513.25 EUR
12/10/202513.38 EUR
12/9/202514.25 EUR
12/8/202516.13 EUR
12/5/202517.25 EUR
12/4/202518.75 EUR
12/3/202521.25 EUR
12/2/202520.50 EUR
12/1/202521.25 EUR
11/28/202521.00 EUR
11/27/202520.87 EUR
11/26/202520.75 EUR
11/25/202521.63 EUR
11/24/202522.88 EUR
11/21/202529.00 EUR
11/20/202531.25 EUR
11/19/202533.75 EUR
11/18/202533.00 EUR
11/17/202531.13 EUR
11/14/202533.63 EUR
11/13/202533.75 EUR
11/12/202533.50 EUR
11/11/202537.50 EUR
11/10/202539.75 EUR
11/7/202545.87 EUR
11/6/202548.75 EUR
11/5/202550.00 EUR
11/4/202542.75 EUR
11/3/202547.00 EUR
10/31/202552.50 EUR
10/30/202551.00 EUR
10/29/202555.00 EUR
10/28/202571.00 EUR
10/27/202565.12 EUR
10/24/202585.75 EUR
10/23/2025106.38 EUR
10/22/2025120.13 EUR
10/21/2025120.13 EUR
10/20/2025155.46 EUR
10/17/202558.86 EUR
10/16/202570.52 EUR
10/15/202579.92 EUR
10/14/202580.20 EUR
10/13/202577.73 EUR
10/10/202589.03 EUR
10/9/202591.86 EUR
10/8/2025100.34 EUR
10/7/2025113.77 EUR
10/6/2025116.31 EUR
10/3/2025120.05 EUR
10/2/2025105.99 EUR
10/1/2025122.67 EUR
9/30/2025125.50 EUR
9/29/2025125.71 EUR
9/26/2025119.98 EUR
9/25/2025129.66 EUR
9/24/2025140.26 EUR
9/23/2025148.39 EUR
9/22/2025162.03 EUR
9/19/2025176.58 EUR
9/18/2025190.79 EUR
9/17/2025197.85 EUR
9/16/2025226.12 EUR
9/15/2025233.18 EUR
9/12/2025282.58 EUR
9/11/2025275.58 EUR
9/10/2025303.85 EUR
9/9/2025332.11 EUR
9/8/2025325.75 EUR
9/5/2025408.43 EUR
9/4/2025367.65 EUR
9/3/2025416.90 EUR
9/2/2025414.08 EUR
9/1/2025466.30 EUR
8/29/2025423.97 EUR
8/28/2025438.10 EUR
8/27/2025487.42 EUR
8/26/2025508.76 EUR
8/25/2025558.23 EUR
8/22/2025529.96 EUR
8/21/2025558.09 EUR
8/20/2025530.10 EUR
8/19/2025529.96 EUR
8/18/2025558.37 EUR
8/15/2025607.69 EUR
8/14/2025611.22 EUR
8/13/2025585.36 EUR
8/12/2025496.05 EUR
8/11/2025501.70 EUR
Access this data via the Eulerpool API
Get Free API Key

Neovacs Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
0.00 EUR
-18.33 M EUR
-14.84 M EUR
Jan 1, 2018
0.00 EUR
-13.08 M EUR
-10.78 M EUR
Jan 1, 2019
0.00 EUR
-8.17 M EUR
-7.55 M EUR
Jan 1, 2020
29,800.00 EUR
-3.49 M EUR
-6.14 M EUR
Jan 1, 2021
22,500.00 EUR
-7.83 M EUR
-11.84 M EUR
Jan 1, 2022
1,100.00 EUR
-6.45 M EUR
-3.55 M EUR
Jan 1, 2023
533,400.00 EUR
-6.91 M EUR
-8.74 M EUR
Jan 1, 2024
291,300.00 EUR
-6.62 M EUR
-32.91 M EUR

Neovacs Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 12:04 AM
 
GROSS INCOMEM EUR
EBITM EUR
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
2009201020112012201320142015201620172018201920202021202220232024
-6.00-7.00-8.00-5.00-5.00-7.00-9.00-14.00-15.00-9.00-5.00-5.00-5.00-5.00-5.00-5.00
-8.00-10.00-10.00-8.00-7.00-9.00-11.00-17.00-18.00-13.00-8.00-3.00-7.00-6.00-6.00-6.00
-6.00-8.00-8.00-7.00-6.00-7.00-4.00-13.00-14.00-10.00-7.00-6.00-11.00-3.00-8.00-32.00
50.0033.33–-12.50-14.2916.67-42.86225.007.69-28.57-30.00-14.2983.33-72.73166.67300.00
16.6316.6316.5316.5717.7023.46––0.010.01––––––
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Neovacs generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Neovacs retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Neovacs's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Neovacs has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Neovacs's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Neovacs stock margins

The Neovacs margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Neovacs. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Neovacs.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
-11.19 %
- %
- %
Jan 1, 2018
-11.19 %
- %
- %
Jan 1, 2019
-11.19 %
- %
- %
Jan 1, 2020
-302.68 %
-11,717.11 %
-20,613.09 %
Jan 1, 2021
-2,055.11 %
-34,790.67 %
-52,610.22 %
Jan 1, 2022
-52,390.91 %
-585,909.13 %
-322,590.92 %
Jan 1, 2023
5.49 %
-1,295.01 %
-1,639.20 %
Jan 1, 2024
-11.19 %
-2,273.15 %
-11,299.14 %

Neovacs Stock Revenue, EBIT, Earnings per Share

The Neovacs earnings per share therefore indicates how much revenue Neovacs has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2017
0.00 EUR
-2.66 B EUR
-2.15 B EUR
Jan 1, 2018
0.00 EUR
-1.22 B EUR
-1.01 B EUR
Jan 1, 2019
0.00 EUR
0.00 EUR
0.00 EUR
Jan 1, 2020
0.00 EUR
0.00 EUR
0.00 EUR
Jan 1, 2021
0.00 EUR
0.00 EUR
0.00 EUR
Jan 1, 2022
0.00 EUR
0.00 EUR
0.00 EUR
Jan 1, 2023
0.00 EUR
0.00 EUR
0.00 EUR
Jan 1, 2024
1.46 B EUR
-33.11 B EUR
-164.57 B EUR

Neovacs business model & stock analysis

Neovacs Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Neovacs historical P/E ratio, EBIT multiple, and P/S ratio

Neovacs annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Neovacs shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2017
0.01 Stocks
Jan 1, 2018
0.01 Stocks
Jan 1, 2019
0.01 Stocks
Jan 1, 2020
0.01 Stocks
Jan 1, 2021
0.01 Stocks
Jan 1, 2022
0.01 Stocks
Jan 1, 2023
0.01 Stocks
Jan 1, 2024
0.00 Stocks

Neovacs stock splits

In Neovacs's history, there have been no stock splits.
Price targets and forecasts for Neovacs are not yet available.

Neovacs shareholder structure

% Name
74.50000%
Neovacs SA Managers and Directors
Neovacs SA Managers and Directors

Neovacs Executives and Management Board

8 members · avg. age 60 · 13 % women

VS

Mr. Vincent Serra (54)

Chief Operating Officer, Chief Scientific Officer

188,798.00 EUR

Management

HB

Mr. Hugo Brugiere

Chairman of the Board, Chief Executive Officer · since 2020

85,000.00 EUR
BF

Mr. Bernard Fanget

Vice President - Pharmaceutical Affairs

–

Board of Directors

MH

Monsieur Baudouin Hallo

Director

9,000.00 EUR
JB

Mr. Jean-Jacques Bertrand (66)

Director · since 2003

6,000.00 EUR
DZ

Mr. Daniel Zagury

Director

6,000.00 EUR
OD

Dr. Olivier Dhellin

Director of Pharmaceutical Development

–
MH

Mme. Muriel Haim

Director

–

Neovacs Supply Chain

Frequently asked questions about Neovacs

9 analysts currently rate the Neovacs stock: 8 recommend buying, 1 holding and 0 selling.

Neovacs Analyst Price Targets 2026

No history available for Neovacs.

The revenue cannot currently be calculated for Neovacs.

The profit cannot currently be calculated for Neovacs.

The P/E ratio cannot be calculated for Neovacs at the moment.

The P/S cannot be calculated for Neovacs currently.

The Eulerpool Quality Score for Neovacs is 4/10.

The ISIN of Neovacs is FR0014010856. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Neovacs is A1CVKR. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Neovacs is ALNEV.PA. The ticker symbol is used to trade Neovacs shares on the stock exchange.

Neovacs paid dividends every year for the past 0 years.

Neovacs is assigned to the 'Health' sector.

The dividends of Neovacs are distributed in EUR.

All fundamentals and in-depth analysis of Neovacs

Our stock analysis for Neovacs stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neovacs. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Neovacs Stock
Neovacs Revenue→
Neovacs Stock
Neovacs Net Income→
Neovacs Stock
Neovacs P/E→
Neovacs Stock
Neovacs P/S→
Neovacs Stock
Neovacs EBIT→
Neovacs Stock
Neovacs Dividend→
Neovacs Stock
Neovacs Directors Dealings→
Neovacs Stock
Neovacs Stocks→
Neovacs Stock
Neovacs Market capitalization→
Neovacs Stock
Neovacs Debt→
Neovacs Stock
Neovacs Liabilities→
Neovacs Stock
Neovacs Equity→
Neovacs Stock
Neovacs AAQS→
Neovacs Stock
Neovacs Employees→
Neovacs Stock
Neovacs ROE→
Neovacs Stock
Neovacs ROA→
Neovacs Stock
Neovacs ROCE→
Neovacs Stock
Neovacs News→
Neovacs Stock
Neovacs Analyst Price Targets→

Health Stocks

Nephro Care IndiaNeOnc Technologies HoldingsNestmedicNeola MedicalNet Medical Xpress SolutionsNeogenomicsNetcareNeogenNetraMark HoldingsNeofect CoNeucaNeoCore Technology CoAll Stocks A–Z →